At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy and Safety of Combination Moxidectin and Albendazole, Ivermectin and Albendazole and Albendazole Alone in Adolescents and Adults Infected With Trichuris Trichiura: a Randomized Controlled Trial
In Brief
A Phase 3 clinical trial evaluating Moxidectin 2 mg Oral Tablet, Albendazole 400 mg Oral Tablet, and 1 other intervention for Trichuriasis and 2 related conditions. Completed, enrolled 255 participants across 1 site.
Detailed Summary
This study is a double-blind randomized controlled superiority trial aiming at providing evidence on the efficacy and safety of co-administered moxidectin and albendazole versus albendazole monotherapy (standard of care) against whipworm (T. trichiura) infections in adolescents and adults (12-60 years) in Côte d'Ivoire. One arm of patients will be treated with albendazole-ivermectin. As measure of efficacy of the treatment the cure rate (percentage of egg-positive subjects at baseline who become egg-negative after treatment) will be determined 14-21 days post-treatment.
Study Details
Timeline
Interventions
Tablets of 2 mg moxidectin
Tablets of 400 mg albendazole
Tablets of 3 mg ivermectin